Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 3.6 MB)

  Published:

  16 December 2020

• Final appraisal determination committee papers (PDF 1.04 MB)

  Published:

  16 December 2020